153 related articles for article (PubMed ID: 9743466)
1. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
[TBL] [Abstract][Full Text] [Related]
2. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
Giles RV; Spiller DG; Green JA; Clark RE; Tidd DM
Blood; 1995 Jul; 86(2):744-54. PubMed ID: 7606003
[TBL] [Abstract][Full Text] [Related]
3. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM
Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525
[TBL] [Abstract][Full Text] [Related]
4. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
5. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
6. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
7. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
Spiller DG; Giles RV; Grzybowski J; Tidd DM; Clark RE
Blood; 1998 Jun; 91(12):4738-46. PubMed ID: 9616172
[TBL] [Abstract][Full Text] [Related]
8. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
Smetsers TF; Linders EH; van de Locht LT; de Witte TM; Mensink EJ
Br J Haematol; 1997 Feb; 96(2):377-81. PubMed ID: 9029029
[TBL] [Abstract][Full Text] [Related]
9. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
Clark RE
Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
13. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
14. Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides.
Giles RV; Tidd DM
Anticancer Drug Des; 1992 Feb; 7(1):37-48. PubMed ID: 1311929
[TBL] [Abstract][Full Text] [Related]
15. Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides.
Yamakawa H; Abe T; Saito T; Takai K; Yamamoto N; Takaku H
Bioorg Med Chem; 1998 Jul; 6(7):1025-32. PubMed ID: 9730239
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
Clark RE; Grzybowski J; Broughton CM; Pender NT; Spiller DG; Brammer CG; Giles RV; Tidd DM
Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
[TBL] [Abstract][Full Text] [Related]
17. Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression.
White JR; Gordon-Smith EC; Rutherford TR
Biochem Biophys Res Commun; 1996 Oct; 227(1):118-24. PubMed ID: 8858112
[TBL] [Abstract][Full Text] [Related]
18. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.
Giles RV; Spiller DG; Clark RE; Tidd DM
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):213-20. PubMed ID: 10355827
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
20. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
